Biocryst Pharmaceuticals Inc (BCRX) News Headlines

▮ More

Date

Headline

6/9/2022 7:23:09 AM BioCryst Selects Pint Pharma As Commercial Partner For ORLADEYO In Latin America

4/5/2022 7:41:26 AM BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10/4/2021 7:29:02 AM BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

9/20/2021 7:09:03 AM BioCryst Appoints Amy McKee To Board

9/15/2021 11:25:21 PM U.K's NICE Recommends BioCryst's Orladeyo To Prevent Attacks In HAE Patients

8/11/2021 5:54:28 AM Pre-market Movers: GTIM, UPST, ZME, WAFU, WW, HYRE…

8/10/2021 10:40:22 PM BioCryst Pharma Withdraws Proposed Public Offering

6/16/2021 7:08:23 AM BioCryst Pharma: Israeli Ministry Of Health Accepts Regulatory Submission Of ORLADEYO

6/3/2021 7:13:40 AM BioCryst Says Oral, Once-daily ORLADEYO Is Now Available For Patients With Prescription In Germany

5/12/2021 10:17:22 AM UK Approves BioCryst's Orladeyo To Prevent Attacks In Hereditary Angioedema Patients

3/2/2021 7:15:34 AM BioCryst Submits MAA To UK’s MHRA Seeking Approval Of ORLADEYO To Prevent Attacks In Patients With Hereditary Angioedema

2/3/2021 7:20:34 AM BioCryst Says FDA Approved Supplemental New Drug Application For RAPIVAB

2/2/2021 2:58:34 AM ADMS Gets FDA Nod, ARQT Soars On Psoriasis Trial Data, DVAX Catches Eye, PRTA On Watch

1/22/2021 7:04:42 AM BioCryst Secures Approval Of ORLADEYO In Japan

1/6/2016 6:06:29 AM Jefferies Is Cutting Biocryst Pharmaceuticals Inc (BCRX) 2016 Estimate To -0.54 From -0.41

1/6/2016 6:03:30 AM Jefferies Ups Biocryst Pharmaceuticals Inc (BCRX) To Buy From Hold With $14 Price Target

Older Articles